KromaTiD

Executive Summary

KromaTiD is a biotechnology company founded in 2013, headquartered in Fort Collins, Colorado, that specializes in single-cell genomic integrity analysis for the cell and gene therapy (CGT) sector. Its proprietary KROMASURE™ Platform provides high-resolution cytogenetic data essential for assessing chromosomal structure, copy number, and rearrangements in therapeutic cell lines. As CGT developers face increasing regulatory scrutiny regarding genomic stability and safety, KromaTiD's services address a critical need for reproducible, actionable analytics that de-risk product development and support regulatory compliance. The company's technology enables precise detection of genomic alterations that could impact therapy efficacy or patient safety, positioning it as a key partner for sponsors advancing engineered cell therapies, gene-edited products, and stem cell-based treatments. With growing adoption of CGTs and tightening FDA guidance on genetic characterization, KromaTiD is poised to capture a meaningful share of the CGT quality analytics market, which is expected to expand rapidly as more therapies enter late-stage development and commercialization.

Upcoming Catalysts (preview)

• Q3 2026KROMASURE Platform Commercial Expansion70% success
• Q4 2026Strategic Partnership with Major CGT Developer50% success
• Q1 2027Series A Funding Round Completion60% success